Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a ...

A new study projects that aligning U.S. cholesterol treatment with clinical guidelines could significantly reduce cardiovascular events nationwide. The study, led by researchers at Baltimore-based ...

Besides working on various strategies to drive Keytruda's long-term growth, Merck is also pinning hopes on its new 21-valent pneumococcal conjugate vaccine, Capvaxive, and pulmonary arterial ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers.

MRK’s Cholesterol Drug Meets Goal in Two Late-Stage Studies In a separate press release, Merck announced topline data from two phase III studies, CORALreef HeFH and CORALreef AddOn, which evaluated ...

Merck & Co. won US approval for a shot that protects against RSV, the most common cause of hospitalization among infants.

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines.